These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

556 related items for PubMed ID: 17938326

  • 1. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
    Lopez JP, Wang-Rodriguez J, Chang C, Chen JS, Pardo FS, Aguilera J, Ongkeko WM.
    Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1022-7. PubMed ID: 17938326
    [Abstract] [Full Text] [Related]

  • 2. Gefitinib (Iressa) potentiates the effect of ionizing radiation in thyroid cancer cell lines.
    Lopez JP, Wang-Rodriguez J, Chang CY, Sneh G, Yu MA, Pardo FS, Aguilera J, Ongkeko WM.
    Laryngoscope; 2008 Aug; 118(8):1372-6. PubMed ID: 18475209
    [Abstract] [Full Text] [Related]

  • 3. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).
    Elkind NB, Szentpétery Z, Apáti A, Ozvegy-Laczka C, Várady G, Ujhelly O, Szabó K, Homolya L, Váradi A, Buday L, Kéri G, Német K, Sarkadi B.
    Cancer Res; 2005 Mar 01; 65(5):1770-7. PubMed ID: 15753373
    [Abstract] [Full Text] [Related]

  • 4. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, Ikegami Y, Tsurutani J, Nakatomi K, Kitazaki T, Doi S, Yoshida H, Kohno S.
    Cancer Res; 2005 Feb 15; 65(4):1541-6. PubMed ID: 15735043
    [Abstract] [Full Text] [Related]

  • 5. Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines.
    Galetti M, Petronini PG, Fumarola C, Cretella D, La Monica S, Bonelli M, Cavazzoni A, Saccani F, Caffarra C, Andreoli R, Mutti A, Tiseo M, Ardizzoni A, Alfieri RR.
    PLoS One; 2015 Feb 15; 10(11):e0141795. PubMed ID: 26536031
    [Abstract] [Full Text] [Related]

  • 6. Doxorubicin fails to eradicate cancer stem cells derived from anaplastic thyroid carcinoma cells: characterization of resistant cells.
    Zheng X, Cui D, Xu S, Brabant G, Derwahl M.
    Int J Oncol; 2010 Aug 15; 37(2):307-15. PubMed ID: 20596658
    [Abstract] [Full Text] [Related]

  • 7. Imatinib-mediated inactivation of Akt regulates ABCG2 function in head and neck squamous cell carcinoma.
    Chu TS, Chen JS, Lopez JP, Pardo FS, Aguilera J, Ongkeko WM.
    Arch Otolaryngol Head Neck Surg; 2008 Sep 15; 134(9):979-84. PubMed ID: 18794444
    [Abstract] [Full Text] [Related]

  • 8. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
    Pick A, Wiese M.
    ChemMedChem; 2012 Apr 15; 7(4):650-62. PubMed ID: 22354538
    [Abstract] [Full Text] [Related]

  • 9. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, Ashby CR, Huang Y, Robey RW, Liang YJ, Chen LM, Shi CJ, Ambudkar SV, Chen ZS, Fu LW.
    Cancer Res; 2008 Oct 01; 68(19):7905-14. PubMed ID: 18829547
    [Abstract] [Full Text] [Related]

  • 10. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J, Zhang X, Wang F, Wang X, Yang K, Xu M, To KK, Li Q, Fu L.
    Oncotarget; 2015 Dec 29; 6(42):44643-59. PubMed ID: 26556876
    [Abstract] [Full Text] [Related]

  • 11. EGFR regulates the side population in head and neck squamous cell carcinoma.
    Chen JS, Pardo FS, Wang-Rodriguez J, Chu TS, Lopez JP, Aguilera J, Altuna X, Weisman RA, Ongkeko WM.
    Laryngoscope; 2006 Mar 29; 116(3):401-6. PubMed ID: 16540898
    [Abstract] [Full Text] [Related]

  • 12. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, Bates SE, Shen T, Ashby CR, Fu LW, Ambudkar SV, Chen ZS.
    Cancer Res; 2007 Nov 15; 67(22):11012-20. PubMed ID: 18006847
    [Abstract] [Full Text] [Related]

  • 13. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
    To KK, Poon DC, Wei Y, Wang F, Lin G, Fu LW.
    Biochem Pharmacol; 2015 Sep 01; 97(1):27-37. PubMed ID: 26206183
    [Abstract] [Full Text] [Related]

  • 14. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW.
    Cancer Lett; 2009 Jun 28; 279(1):74-83. PubMed ID: 19232821
    [Abstract] [Full Text] [Related]

  • 15. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
    Nagashima S, Soda H, Oka M, Kitazaki T, Shiozawa K, Nakamura Y, Takemura M, Yabuuchi H, Fukuda M, Tsukamoto K, Kohno S.
    Cancer Chemother Pharmacol; 2006 Nov 28; 58(5):594-600. PubMed ID: 16520985
    [Abstract] [Full Text] [Related]

  • 16. Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells.
    Liu H, Cheng D, Weichel AK, Osipo C, Wing LK, Chen B, Louis TE, Jordan VC.
    Int J Oncol; 2006 Nov 28; 29(5):1237-46. PubMed ID: 17016657
    [Abstract] [Full Text] [Related]

  • 17. Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines.
    Bai XY, Zhang XC, Yang SQ, An SJ, Chen ZH, Su J, Xie Z, Gou LY, Wu YL.
    PLoS One; 2016 Nov 28; 11(3):e0149370. PubMed ID: 26943330
    [Abstract] [Full Text] [Related]

  • 18. ABCG2: the key to chemoresistance in cancer stem cells?
    An Y, Ongkeko WM.
    Expert Opin Drug Metab Toxicol; 2009 Dec 28; 5(12):1529-42. PubMed ID: 19708828
    [Abstract] [Full Text] [Related]

  • 19. Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11.
    Mishra MN, Vangara KK, Palakurthi S.
    Anticancer Res; 2014 Nov 28; 34(11):6345-51. PubMed ID: 25368234
    [Abstract] [Full Text] [Related]

  • 20. Downregulated ABCG2 enhances sensitivity to topoisomerase I inhibitor in epidermal growth factor receptor tyrosine kinase inhibitor-resistant non-small cell lung cancer.
    Ohtsuka K, Ohnishi H, Morii T, Fujiwara M, Kishino T, Ogura W, Chiba M, Matsushima S, Goya T, Watanabe T.
    J Thorac Oncol; 2010 Nov 28; 5(11):1726-33. PubMed ID: 20975373
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.